Immunobiology

The rapid evolution and expansion of applications in targeted cell therapies and immunobiologics has seen significant interest in the use of biological therapies for treating disease, resulting in an evolving and complex patent space. 

Challenges in product efficacy, administration, side effects and costs are driving ongoing research, with IP considerations spanning the preparation of cells, formulations and methods of administration. 

HGFs team of 23 life sciences attorneys, who possess specific immunobiology academic accomplishments and in-house backgrounds, apply a cross-technology approach to building portfolios and data-driven strategies that layer protection and maximise exclusivity periods. 

The team’s extensive insight into regulatory and approval pathways in this area adds a strong commercial focus to the development of economically viable strategies. Furthermore, the multidisciplinary specialists have significant experience in conducting due diligence across every aspect of immunobiology, from genes through to formulation and application processes. 

Working with universities, large pharmaceutical firms and generic companies, HGF creates and protects patents for commercially important products, with significant experience of opposition and appeals before the European Patent Office.

Latest updates

Medical technology most patented subject matter at EPO in 2020

Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …

Read article

Searching for the distinctive

How to streamline the trade mark selection process by conducting effective, in-house ‘dirty searches’. Selecting the right trade mark for your new healthcare product is a critically important task. Consumers …

Read article

The EPO ‘How To’ guide for antibody applications in Europe

The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …

Read article

Personalised drug patenting in Europe

Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …

Read article

The Internet of Medical Things

Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …

Read article

Covid-19 vaccine patent waivers

To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …

Read article
Event - 26th April 2021

World Intellectual Property Day 2021

World Intellectual Property Day is on 26th April. This year’s theme is IP & SME’s: Taking your ideas to market. World IP day 2021 shines a light on the critical role of …

Event details
Event - 18th May 2021

IP & data protection for alternative proteins: how to protect your products in the EU

‘IP & data protection for alternative proteins: how to protect your products in the EU’ webinar will be held on Tuesday 18th May. Join this webinar by BGP, HGF & …

Event details

Let's talk

If you would like to discuss how HGF could help you, contact one of our immunobiology specialists.